INM News and Press, InMed Pharmaceuticals Inc. From 04/04/24

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains previously reported obser...

2024-03-27 17:08:02 ET InMed is the first to advance a rare cannabinoid to human clinical trials InMed Pharmaceuticals is a biopharmaceutical company. They specialize in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high ...

2024-03-27 17:08:02 ET Cost-effective, flexible and high-yield system for manufacturing cannabinoids While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of th...

2024-03-27 17:08:02 ET © 2020 www.B-TV.com . All Rights Reserved. A biosynthesis platform technology Cannabinoids are relative compounds that are the active elements of the cannabis plant. While there are over 100 different cannabinoids. Here are two well-known an...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to comply with NASDAQ’s minimum bid price requirement for the continued listing on the NA...

2024-03-20 08:38:41 ET More on InMed Pharmaceuticals Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals gets 180-Day exte...

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a n...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, includi...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, includi...

2024-02-13 17:45:38 ET More on InMed Pharmaceuticals Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals GAAP EPS of -$0.1...